Innoviva

INVA · Nasdaq · United States

Share price · INVA

$18.40-2.85 (-13.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (1.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-9.5%
  2. 23 Sep 2026-3.5%

    Nothing announced by INVA that day or the session before.

  3. 7 Aug 2026-2.8%

    Nothing announced by INVA that day or the session before.

  4. 1 Jul 2026-3.6%

    Nothing announced by INVA that day or the session before.

  5. 11 Jun 2026-2.4%

    Nothing announced by INVA that day or the session before.

  6. 10 Jun 2026+2.0%
  7. 27 May 2026-2.4%

    Nothing announced by INVA that day or the session before.

  8. 15 May 2026-3.9%
  9. 25 Feb 2026+3.5%
  10. 17 Feb 2026+5.1%

Share of unusual movement by asset

For each asset, the share of INVA's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—91%

No dated announcements about its assets since 14 Oct 2025.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$106M$5.2M$581M$74M$42M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$120M$5.2M$570M$83M$52M operating cash flowreport ↗
2026-Q1$98M$5.2M$603M—$35M operating cash flowreport ↗
2025-Q3$108M$14M$477M—$50M operating cash flowreport ↗
2025-Q2$100M$8.0M$398M—$44M operating cash flowreport ↗
2025-Q1$89M$4.4M$319M$47M$49M operating cash flowreport ↗
2024-Q3$90M$3.5M$261M—$49M operating cash flowreport ↗
2024-Q2$100M$2.6M$217M$35M$44M operating cash flowreport ↗
2024-Q1$78M$3.9M$178M—$37M operating cash flowreport ↗
2023-Q3$67M$4.0M$180M—$44M operating cash flowreport ↗
2023-Q2$81M$15M$173M—$38M operating cash flowreport ↗
2023-Q1$76M$13M$144M—$26M operating cash flowreport ↗
2022-Q3$67M$12M$301M+ $0.3M short-term inv.—$16M operating cash flowreport ↗
2022-Q2$108M$14M$284M—$79M operating cash flowreport ↗
2022-Q1$90M$5.8M$217M—$98M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$411M$31M$551M—$197M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$359M$14M$305M—$189M operating cash flowreport ↗
2023-FY$310M$34M$194M—$141M operating cash flowreport ↗
2022-FY$331M$41M$291M—$202M operating cash flowreport ↗
2021-FY$392M$0.6M$202M+ $0 short-term inv.—$364M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-20Raifeld Pavel · director, Chief Executive OfficerTax withholding1,130$21.00$24KForm 4
2026-08-20Basso Stephen · Chief Financial OfficerTax withholding558$21.00$12KForm 4
2026-08-20Zhen Marianne · Chief Accounting OfficerTax withholding1,127$21.00$24KForm 4
2026-05-20Zhen Marianne · Chief Accounting OfficerTax withholding1,127$22.24$25KForm 4
2026-05-20Raifeld Pavel · director, Chief Executive OfficerTax withholding1,130$22.24$25KForm 4
2026-05-20Basso Stephen · Chief Financial OfficerTax withholding559$22.24$12KForm 4
2026-05-18Linden Josephine · directorAward / grant5,733——Form 4
2026-05-18Linden Josephine · directorAward / grant9,461——Form 4